Description

Zortemib (Bortezomib Injection) – Product Description Zortemib contains Bortezomib, a prescription targeted anti-cancer medicine used for the treatment of multiple myeloma and mantle cell lymphoma (MCL). It belongs to the proteasome inhibitor class of medicines and works by blocking the 26S proteasome, causing the accumulation of damaged proteins inside cancer cells. This disruption leads to cancer cell death and helps slow the progression of the disease. Zortemib is administered by qualified healthcare professionals as an intravenous (IV) or subcutaneous (SC) injection. It may be used alone or in combination with other anti-cancer medicines depending on the patient's diagnosis, treatment stage, and clinical condition. Active Ingredient Bortezomib Dosage Form Sterile Injection (Intravenous or Subcutaneous) Therapeutic Indications Multiple Myeloma Mantle Cell Lymphoma (MCL) Other approved hematologic malignancies as determined by the treating oncologist How It Works Bortezomib selectively inhibits the 26S proteasome, preventing the breakdown of proteins within cancer cells. This causes cellular stress, disrupts normal cell function, and triggers programmed cancer cell death (apoptosis), helping to control tumor growth. Key Features Targeted therapy for multiple myeloma and mantle cell lymphoma Proteasome inhibitor with a well-established role in hematologic oncology Can be administered by intravenous or subcutaneous injection May be used as monotherapy or in combination treatment regimens Manufactured according to stringent pharmaceutical quality standards Storage Store according to the manufacturer's recommendations. Protect from moisture, excessive heat, and direct light. Keep out of reach of children. Note: Zortemib (Bortezomib Injection) is a prescription-only medicine and should be administered only under the supervision of a qualified oncologist. Regular monitoring of blood counts, liver function, kidney function, and neurological status is recommended during treatment.